Rivastigmine in Parkinson's disease dementia

Bibliography

• Levy G, Tang MX, Louis ED, et al. Neurology 2002;59:1708-13
   PubMed Web of Science ®Google Scholar
• Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 1990;95:239-58
   PubMed Web of Science ®Google Scholar
• Hietnem M, Teravainen H. The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:244-9
   PubMed Web of Science ®Google Scholar
• Martin WE, Loewenson RB, Resch JA, Baker AB. Parkinson's disease: clinical analysis of 100 patients. Neurology 1973;23:783-90
   PubMed Web of Science ®Google Scholar
• Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127:550-60
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44
   PubMed Web of Science ®Google Scholar
• Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-37
   PubMed Web of Science ®Google Scholar
• Camicioli R, Fisher N. Parkinson's disease with dementia and dementia with Lewy bodies. Prog Clin Neurosci 2004;31(1):7-21
   Web of Science ®Google Scholar
• Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106(Pt 2):257-70
   PubMed Web of Science ®Google Scholar
• Huber SJ, Shuttleworth EC, Freidenberg DL. Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Arch Neurol 1989;46:1287-91
   PubMed Web of Science ®Google Scholar
• Pahwa R, Paolo A, Troster A, Koller W. Cognitive impairment in Parkinson's disease. Eur J Neurol 1998;5:431-41
   PubMed Web of Science ®Google Scholar
• Zgaljardic DJ, Foldi NS, Borod JC. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transm 2004;111:1287-301
   PubMed Web of Science ®Google Scholar
• Williams SW, Byrne EJ, Stokes P. The treatment of diffuse Lewy body disease: a pilot study of five cases. Int J Geriatr Psychiatry 1993;8:731-9
   Web of Science ®Google Scholar
• Byrne J. Diffuse lewy body disease: disease, spectrum disorder of variety of Alzheimer's disease. Int J Geriatr Psychiatry 1992;7:229-34
   Web of Science ®Google Scholar
• Byrne J. Lewy body dementia. J R Soc Med 1997;90(Suppl 32):14-5
   PubMed Web of Science ®Google Scholar
• McKeith IG, Galasko DR, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
   PubMed Web of Science ®Google Scholar
• Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorders Society Task Force. Mov Disord 2007;22(16):2314-24
   PubMed Web of Science ®Google Scholar
• Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies, but not AD. Neurology 2001;56:643-9
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000;15:613-26
   PubMed Web of Science ®Google Scholar
• Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001;14:499-504
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63
   PubMed Web of Science ®Google Scholar
• Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5:225-9
   PubMed Web of Science ®Google Scholar
• Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-81
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003;26:643-59
   PubMed Web of Science ®Google Scholar
• Aarsland D, Mosimann UP, Mckeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164-71
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-97
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983;10:1185-201
   PubMed Web of Science ®Google Scholar
• Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999;22:273-80
   PubMed Web of Science ®Google Scholar
• Von Engelhardt J, Eliava M, Meyer AH, et al. Functional characterization of intrinsic cholinergic interneurons in the cortex. J Neurosci 2007;27:5633-42
   PubMed Web of Science ®Google Scholar
• Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-9
   PubMed Web of Science ®Google Scholar
• Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-8
   PubMed Web of Science ®Google Scholar
• Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-10
   PubMed Web of Science ®Google Scholar
• Lane R, He Y, Morris C, et al. BuChE-K abd APOE e4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009;23:392-400
   Google Scholar
• Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol 1989;105:221-32
   PubMed Web of Science ®Google Scholar
• Lehericy S, Hirsch EC, Cervera-Pierot P, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993;330:15-31
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;68:253-4
   PubMed Web of Science ®Google Scholar
• Fujishiro H, Umegaki H, Isojima D, et al. Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies. Acta Neuropathol 2006;111:109-14
   PubMed Web of Science ®Google Scholar
• Woolf NJ, Jacobs RW, Butcher LL. The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neurosci Lett 1989;96:277-82
   PubMed Web of Science ®Google Scholar
• Shiozaki K, Iseki E, Hino H, Kosaka K. Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study. J Neurol Sci 2001;193:23-8
   PubMed Web of Science ®Google Scholar
• Colloby SJ, Pakrasi S, Firbank MJ, et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 2006;33:423-9
   PubMed Web of Science ®Google Scholar
• Perry E, Martin-Ruiz C, Lee M, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000;393:215-22
   PubMed Web of Science ®Google Scholar
• Gotti C, Moretti M, Bohr I, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 2006;23:481-9
   PubMed Web of Science ®Google Scholar
• O'Brien JT, Colloby SJ, Pakrasi S, et al. Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage 2008;40:1056-63
   PubMed Web of Science ®Google Scholar
• Rei RT, Sabbagh MN, Corey-Bloom J, et al. Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiol Aging 2000;21:741-6
   PubMed Web of Science ®Google Scholar
• Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav 2001;70:571-9
   PubMed Web of Science ®Google Scholar
• Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000;20(1):1-12
   PubMed Web of Science ®Google Scholar
• Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431-8
   PubMed Web of Science ®Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47
   PubMed Web of Science ®Google Scholar
• Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998;97:244-50
   PubMed Web of Science ®Google Scholar
• Mercier F, Lefevre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsule. Curr Med Res Opin 2007;23(12):3199-204
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N, et al. A six month double blind, randomized placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastimine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
   PubMed Web of Science ®Google Scholar
• Wesnes KA, Mckeith I, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-6
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-61
   PubMed Web of Science ®Google Scholar
• Burn D, Emre M, Mckeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-907
   PubMed Web of Science ®Google Scholar
• Barone P, Burn DJ, van Laar T, et al. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008;23:1532-40
   PubMed Web of Science ®Google Scholar
• Ballard C, Lane R, Barone P, et al. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60:639-45
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-6
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-8
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627-39
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology 2006;66(7):996-1002
   Google Scholar
• Burn DJ, Mckeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003;18(Suppl 6):S72-9
   PubMed Web of Science ®Google Scholar
• Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123-30
   PubMed Web of Science ®Google Scholar
• Yang LP, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type. CNS Drugs 2007;21:957-65
   PubMed Web of Science ®Google Scholar
• Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 2003;25:1634-53
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-707
   PubMed Web of Science ®Google Scholar
• Rongve A, Aarsland D. Management of Parkinson's disease dementia: practical considerations. Drugs Aging 2006;23:807-22
   PubMed Web of Science ®Google Scholar
• Caballol N, Marti MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007;22(Suppl 17):S358-66
   PubMed Web of Science ®Google Scholar